Bristol-Myers Squibb
BMY
$0.22 (-0.41%)
1D
1W
3M
1Y
5Y
ALL
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 1 day ago • BMY
These 2 Healthcare Stocks Just Declared Dividend Raises
Zacks Investment Research • 1 day ago • BMY
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
PRNewsWire • 2 days ago • BMY
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
CNBC Television • 3 days ago • BMY
Final Trade: JNJ, NVO, UBER, BMY
Benzinga • 3 days ago • BMY
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.